JNJ - Johnson & Johnson
127.26 +0.43 (0.34%)
Pre-market: 6:25AM EDT
| Previous close | 126.66 |
| Open | 126.88 |
| Bid | 126.54 x 100 |
| Ask | 127.65 x 100 |
| Day's range | 125.78 - 127.30 |
| 52-week range | 122.15 - 148.32 |
| Volume | 7,501,870 |
| Avg. volume | 8,031,553 |
| Market cap | 340.239B |
| Beta | 0.59 |
| PE ratio (TTM) | 267.57 |
| EPS (TTM) | 0.47 |
| Earnings date | 17 Jul 2018 |
| Forward dividend & yield | 3.36 (2.57%) |
| Ex-dividend date | 2018-02-26 |
| 1y target est | 149.05 |
- Market Realist•14 hours ago
Johnson & Johnson’s Revenues Continued to Rise in 1Q18
Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.
- Market Realist•19 hours ago
Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.
- Motley Fool•20 hours ago
Johnson & Johnson's Top-Line Growth Isn't What It Seems
The company’s double-digit growth comes with some caveats.
- Motley Fool•21 hours ago
Geron Corporation: The Clock Is Ticking
Geron's stock has been a magnet for short-sellers, but the long thesis remains intact.
- Market Realist•21 hours ago
Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.
- Market Realist•23 hours ago
Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.
- Motley Fool•2 days ago
3 Things You Should Know About Today's Top Entrepreneurs
A new wave of innovation will change several of America's most established industries. Here are three important takeaways for investors.
- Motley Fool•2 days ago
Johnson & Johnson's First-Quarter 2018 Earnings Review
We discuss the pros and cons for J&J’s latest quarterly results, plus Alkermes gets a do-over and Celldex flops.
- Barrons.com•3 days ago
[$$] Square, eBay, and the Future of Money
Earnings per share were higher despite a higher tax rate and a lower contribution from other income. What we didn’t like about the first quarter: 1) the pharma mix was not optimal, as key drugs Actelion, Darzalex, and Xarelto all missed our estimate. U.S. Remicade was down 16% Y/Y, in line with our estimate, but we were hoping for better.
- Zacks•4 days ago
Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
- Zacks•4 days ago
J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.
- Zacks•4 days ago
Dow 30 Stock Roundup: AmEx, Goldman, IBM, JNJ, P&G, UNH Earnings Impress
The Dow experienced a particularly volatile week as earnings results took center stage.
- CNBC•4 days ago
Johnson & Johnson is betting on vision care and expanding beyond contacts
J&J has added surgical products and a contact subscription service to its lineup of Acuvue contact lenses.
CNBC•4 days agoChina's pharmaceutical industry is poised for major growth
There's one major industry where China could dominate both as a maker and consumer: health care.
- Zacks•5 days ago
Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings
Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.
- Motley Fool•5 days ago
3 Drugs That Are Moving the Needle at Johnson & Johnson
Johnson & Johnson owes a lot of its early success this year to rapidly growing sales of three key products.
- Barrons.com•6 days ago
After the Bell: Dow Drops 38 Points Because…IBM
The major equity indexes barely moved today, as a postearnings drop from International Business Machines (IBM) was canceled out by gains from Textron (TXT), Intuitive Surgical (ISRG), and others. Ultimately, it shows once again that it's as much a market of stocks as it is a stock market. The Dow Jones Industrial Average dropped 38.56 points, or 0.2%, to 24,748.07, while the S&P 500 ticked up 0.1% to 2708.64, and the Nasdaq Composite advanced 0.2% to 7295.24.
CNBC•6 days agoKentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves'
"I'm not on board with just about anything that he does," Gov. Matt Bevin said of Kentucky Attorney General Andy Beshear.
- Reuters - UK Focus•6 days ago
Buy a pencil, educate a child: British firms boost spending on businesses doing good
A campaign to boost British businesses with a social mission has attracted major names, from banking to pharmaceuticals, but is far from its goal of channelling 1 billion pounds ($1.4 billion) into the sector by 2020, its founders said on Wednesday. Pharmaceutical company Johnson & Johnson (NYSE: JNJ - news) , consulting firm PwC and Santander bank have signed up to the Buy Social Corporate Challenge, launched in 2016 by Social Enterprise UK (SEUK), which represents the growing sector. About a dozen companies participating in the scheme have spent a total of 45 million pounds over the last two years with organisations that aim to address social and environmental issues as well as making a profit, SEUK said on Wednesday.
- MarketWatch•6 days ago
IBM and J&J stocks cut 100 points from Dow industrials in early trading
The Dow Jones Industrial Average on Wednesday morning was wrestling with sharp declines in IBM and Johnson & Johnson. Shares of International Business Machines Corp. were off 7.2%, or about $11.50, which equates to a drop of about 80 points, while J&J's stock was contributing a further 24-point retreat in the benchmark, down 2.7%, or about $3.50, in recent action. Overall, the Dow was still managing to rise by about 24 points, or less than 0.1%, at 24,802, with J&J and IBM's tumble slightly offset by gains in Home Depot Inc. Caterpillar Inc. and Boeing Co. 's stocks.
- The Wall Street Journal•6 days ago
[$$] Johnson & Johnson Raises Sales Outlook
Johnson & Johnson reported higher-than-expected sales in its latest quarter and boosted its sales outlook for the year despite ongoing pricing pressures for its prescription drugs and medical devices. J&J said it planned to cut costs in its supply chain by $600 million to $800 million a year by 2022. To carry out the changes, J&J expects it will take $1.9 billion to $2.3 billion in charges over the next several years.
- Bloomberg•7 days ago
What to Look for as First-Quarter Earnings Hit Around the Globe
Trade, taxes and China are the main themes to watch for heading into first-quarter earnings, along with a spate of potential deals.
- Associated Press•7 days ago
UnitedHealth and Alphabet climb; Tesla and Comerica skid
Stocks that moved substantially or traded heavily Tuesday: UnitedHealth Group Inc., up $8.23 to $238.55 The health insurer raised its annual profit forecast after a strong first quarter. Tesla Inc., down ...
Reuters•7 days agoWall Street rises on earnings hopes, Netflix soars
U.S. stock indexes rallied on Tuesday on broad-based gains while Netflix and UnitedHealth earnings impressed investors and boosted optimism about the U.S. corporate reporting season. Shares in Netflix (NFLX.O), the first of Wall Street's leading momentum stocks to report earnings, rose 9 percent to close at a record high after the video-streaming pioneer smashed analysts' quarterly subscriber estimates. Amazon.com (AMZN.O) was the S&P's biggest boost with a 4 percent jump, helped by Netflix results but also by signs the U.S. Supreme Court is hesitant to let states force out-of-state online retailers to collect sales taxes on purchases.
- Investor's Business Daily•7 days ago
J&J Boosts Sales Forecast On Growing Demand For Cancer Drugs
Johnson & Johnson nudged its 2018 sales guidance higher Tuesday as demand for cancer drugs surged in the first quarter, even as its blockbuster Remicade continued to face competitive pressure.
